Evidence map›Paper›PMID 37760486›Full record

ArticleCancers2023

Personalized Breast Cancer Screening: A Risk Prediction Model Based on Women Attending BreastScreen Norway.

Javier Louro, Marta Román, Nataliia Moshina, Camilla F Olstad, Marthe Larsen, Silje Sagstad, Xavier Castells, Solveig Hofvind

Abstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Javier LouroDepartment of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute, 08003 Barcelona, Spain.ORCID 0000-0002-2985-3301
Marta RománDepartment of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute, 08003 Barcelona, Spain.
Nataliia MoshinaSection for Breast Cancer Screening, Cancer Registry of Norway, 0304 Oslo, Norway.
Camilla F OlstadSection for Breast Cancer Screening, Cancer Registry of Norway, 0304 Oslo, Norway.
Marthe LarsenSection for Breast Cancer Screening, Cancer Registry of Norway, 0304 Oslo, Norway.
Silje SagstadSection for Breast Cancer Screening, Cancer Registry of Norway, 0304 Oslo, Norway.ORCID 0009-0003-3193-1158
Xavier CastellsDepartment of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute, 08003 Barcelona, Spain.
Solveig HofvindSection for Breast Cancer Screening, Cancer Registry of Norway, 0304 Oslo, Norway.ORCID 0000-0003-0178-8939

Funding

Instituto de Salud Carlos III FEDER PI/00047
6 · The paper itself

Abstract

backgroundWe aimed to develop and validate a model predicting breast cancer risk for women targeted by breast cancer screening.

methodThis retrospective cohort study included 57,411 women screened at least once in BreastScreen Norway during the period from 2007 to 2019. The prediction model included information about age, mammographic density, family history of breast cancer, body mass index, age at menarche, alcohol consumption, exercise, pregnancy, hormone replacement therapy, and benign breast disease. We calculated a 4-year absolute breast cancer risk estimates for women and in risk groups by quartiles. The Bootstrap resampling method was used for internal validation of the model (E/O ratio). The area under the curve (AUC) was estimated with a 95% confidence interval (CI).

resultsThe 4-year predicted risk of breast cancer ranged from 0.22-7.33%, while 95% of the population had a risk of 0.55-2.31%. The thresholds for the quartiles of the risk groups, with 25% of the population in each group, were 0.82%, 1.10%, and 1.47%. Overall, the model slightly overestimated the risk with an E/O ratio of 1.10 (95% CI: 1.09-1.11) and the AUC was 62.6% (95% CI: 60.5-65.0%).

conclusionsThis 4-year risk prediction model showed differences in the risk of breast cancer, supporting personalized screening for breast cancer in women aged 50-69 years.

Indexed as

area under curvebreast neoplasmsearly detection of cancerfemaleretrospective studies

Identifiers

PMID37760486
PMCPMC10526465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.